<?xml version="1.0" encoding="UTF-8"?>
<fig id="vaccines-08-00142-f004" orientation="portrait" position="float">
 <label>Figure 4</label>
 <caption>
  <p>Enforced replication is essential for vaccination success of VSV-EBOV administration. 
   <bold>A</bold> + 
   <bold>B</bold>: VSV-EBOV titers (
   <bold>A</bold>, 
   <italic>n</italic> = 6–7) or relative VSV-NP expression (
   <bold>B</bold>, 
   <italic>n</italic> = 6–7) of WT and 
   <italic>CD169</italic>-Cre
   <sup>+/
    <italic>ki</italic>
   </sup> x 
   <italic>Usp18</italic>
   <sup>fl/fl</sup> mice in draining lymph nodes of mice subcutaneously infected with 2 × 10
   <sup>6</sup> PFU VSV-EBOV 16 h p.i. 
   <bold>C</bold>: Immunofluorescence of lymph node sections from WT and 
   <italic>CD169</italic>-Cre
   <sup>+/
    <italic>ki</italic>
   </sup> x 
   <italic>Usp18</italic>
   <sup>fl/fl</sup> mice 16 h after subcutaneous injection of 2 × 10
   <sup>6</sup> PFU VSV-EBOV. Staining for Ebola virus GP (red) and CD169 (blue). One representative staining per group of two independent experiments (
   <italic>n</italic> = 6–7). 
   <bold>D</bold>: Relative expression of 
   <italic>Ifna4</italic> and 
   <italic>Ifnb1</italic> in draining lymph nodes after infection as described in 
   <bold>A</bold>. (
   <italic>n</italic> = 6–7, 
   <italic>naïve</italic> WT mice 
   <italic>n</italic> = 4). 
   <bold>E</bold>: VSV-EBOV neutralizing total Ig in mice i.m. infected with 2 × 10
   <sup>6</sup> PFU VSV-EBOV. (
   <italic>n</italic> = 6) 
   <italic>* p</italic> &lt; 0.05, 
   <sup>#</sup>
   <italic>p</italic> &lt; 0.001, 
   <sup>##</sup>
   <italic>p</italic> &lt; 0.0001 (Student’s 
   <italic>t</italic>-test, 
   <bold>A</bold>,
   <bold>B</bold>,
   <bold>D</bold>), (Two-way-Anova, 
   <bold>E</bold>). Data are representative of two (
   <bold>A</bold>–
   <bold>E</bold>) experiments (mean ± SEM (
   <bold>A,B,D,E</bold>)).
  </p>
 </caption>
 <graphic xlink:href="vaccines-08-00142-g004" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
